HomeAI · summaries
Storia in 2 fonti
Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
scmp.com
Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing
Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.
- ·
cnbc.com
Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.